Finnish adult ADHD patient found medical cannabis more helpful than Ritalin over five years | Research

The takeaway

A detailed case report describes a Finnish adult diagnosed with ADHD at 33 who found prescribed medical cannabis (Bedrocan and Bediol) more effective than methylphenidate for frustration tolerance, anger, boredom, and concentration over five years of use.

Adults with ADHD who haven't responded to standard treatments, and anyone interested in cannabis for cognitive and emotional conditions.

After 5 years, patient reported better frustration tolerance and concentration with cannabis than Ritalin

What the researchers found

After experiencing adverse effects from methylphenidate and alternative medications, the patient was prescribed Bedrocan (THC-dominant) for ADHD symptom relief and Bediol (THC+CBD) to moderate the THC effects and improve sleep. Over 5 years, the THC-dominant product helped with frustration tolerance, anger outbursts, boredom, and concentration.

Why it matters

ADHD treatment in adults relies heavily on stimulant medications that many patients cannot tolerate. This detailed case adds to limited evidence that some ADHD patients may benefit from cannabinoid therapeutics, particularly for emotional regulation symptoms.

The numbers in context

Patient diagnosed with ADHD at age 33. Initial treatment: Ritalin 10mg twice daily. Adverse effects led to alternatives. Medical cannabis prescribed 2010: Bedrocan (THC-dominant) and Bediol (THC+CBD). 5-year treatment period. Symptoms improved: frustration tolerance, anger, boredom, concentration.

How the study worked

Detailed single-patient case report with sociological framing, describing a patient's journey from methylphenidate to medical cannabis for adult ADHD, prescribed through Germany and confirmed by Finnish neurologist. Includes brief literature review of cannabis for ADHD.

What this study cannot tell us

Single case report, the weakest evidence level. Patient self-reported outcomes without objective measures. No placebo comparison. The patient sought cannabinoid treatment actively, suggesting potential bias. Regulatory and cultural context (Finland) may affect generalizability.

How to read the evidence

Preliminary: single case report with subjective outcomes over five years.

When this study was published

Published in 2019.

The bigger picture

A Lancet review cited in the memory found no effect of cannabinoids for ADHD in small trials. This case report suggests the disconnect may be between group-level trial results and individual patient responses, highlighting the need for personalized approaches.

Questions still open

Could a subgroup of ADHD patients benefit from cannabinoids while the average trial effect is null? Is the emotional regulation benefit distinct from cognitive effects? Would standardized outcome measures confirm the patient's reported improvements?

Common questions

Can cannabis help with ADHD?

This case report describes one adult whose ADHD symptoms improved with medical cannabis after methylphenidate failed. However, small clinical trials have not found group-level effects, suggesting cannabis may help some individuals but not most.

Why did this patient use two different cannabis products?

Bedrocan (THC-dominant) was used for ADHD symptom relief, while Bediol (containing both THC and CBD) was added to moderate THC's excessive effects and improve sleep. The combination allowed fine-tuning of the therapeutic effect.

Read the original research

Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland.

Medical cannabis and cannabinoids, 1(2), 112-118

View on PubMed ↗Publisher’s paper ↗

Citation

Hupli, Aleksi Mikael Markunpoika. (2019). Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland.. Medical cannabis and cannabinoids, 1(2), 112-118. https://doi.org/10.1159/000495307